Cetya Therapeutics, Inc.

Denver, CO Research And Development

UEI
LJWQMH4FA7P3
CAGE
61CN7
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
3134 Wyandot St, Denver, CO 80211, USA
Website
cetya-therapeutics.com
Founded
2012
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
In vivo studies of a novel hdac inhibitor for treating hemoglobin disorders R42HL136068 National Heart Lung and Blood Institute (NIH) $1,063,567
Novel hdac inhibitors for treatment of hemoglobinopathies R41HL136068 National Heart Lung and Blood Institute (NIH) $241,742

Quick answers

Is Cetya Therapeutics, Inc. registered in SAM.gov?

Yes. Cetya Therapeutics, Inc.'s SAM.gov registration is active through May 28, 2027.

What is Cetya Therapeutics, Inc.'s most recent federal award?

Cetya Therapeutics, Inc.'s most recent federal grant award is In vivo studies of a novel hdac inhibitor for treating hemoglobin disorders (R42HL136068), from National Heart Lung and Blood Institute (NIH), on September 1, 2017.

On GovTribe

See Cetya Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login